[Evaluation of medicines price listed on the official bulletins in Morocco (2014-2019)]. / Évaluation du prix des médicaments figurant sur les bulletins officiels au Maroc (2014­2019).

OBJECTIVES: This study shows the evolution of medicines prices over the period April 2014 to September 2019 in order to provide an overview of the situation following the adoption of the new method for setting drug prices in Morocco. METHODS: The analysis concerned official bulletins relating to the Public Selling Price of drugs in Morocco published between April 2014 and September 2019 as part of a retrospective study. RESULTS: Out of a total of 7292 medicines, 35.9% were unchanged in price, 26.2% were new and 0.3% had a price increase. The decrease affected 37.7% equivalent to 2747 medicines. Of these, 38.6% decreased in price in 2014 and 84.13% had only one decrease. Medicines with a retail price of between 5 and 10 Euros were the most affected by the decrease. Decreases of less than 1% of the selling price represented 27.7% against 0.3% whose decrease exceeded 70% of the price. The largest decreases in number were recorded in 2014. Some medicines saw declines of up to 78.6%. The most affected price brackets in percentage terms were those with a retail price above 20 Euros. CONCLUSIONS: Following the adoption of the new decree on the pricing of medicines in 2013 in Morocco, several decreases were recorded and concerned all therapeutic classes. The percentages of the decreases in Moroccan Dirham as well as in percentage were very variable.

Benzodiazepines use in Morocco: A nation wide consumption database study between 2004 and 2017.

Although information exists regarding the rate of benzodiazepines (BZDs) use in different countries, little information is available concerning the BZDs consumption in Morocco. To describe prescription rate in Morocco, a retrospective descriptive analysis of BZDs and their agonists use with the instituteIQIVIA database was performed during the period 2004-2017. The obtained data provide a dynamic approach to total BZDs consumption using an annual collection of sales data in Morocco and were expressed in terms of daily defined doses/ 1000 inhabitants / day. Data analysis showed that the major BZDs sold in Morocco were Alprazolam, Bromazepam, Nordazepam, Lorazepam, Parazepam, Diazepam and two benzodiazepine agonists, Zolpidem and Zopiclone. The Bromazepam was the molecule the most consumed during 2004-2016. In 2017, Alprazolam was the most consumed followed by Bromazepam, Nordazepam, Zolpidem, Lorazepam, Parazepam, Diazepam, Dipotassium clorazepate, Dipotassium Clorazypate and Zopiclone with 0.94, 0.91, 0.6, 0.55, 0.45, 0.32, 0.18, 0.18, 0.07 and 0.05 daily defined doses/ 1000 inhabitants / day respectively. The total amount consumed each year for all BZDs and their agonists in Morocco was 2.69, 2.77, 3, 3.17, 3.32, 3.54, 3.61, 3.81, 4.06, 4.30, 4.06, 3.94, 3.78 and 3.66 daily defined doses/ 1000 inhabitants / day, respectively during 2004-2017. To our knowledge, this is the first study that describes the consumption of BZDs and their agonists (Zolpidem, Zopiclone) in Morocco. This data may help the analytical toxicology laboratory and health organizations operating in the field of analytical biochemistry to develop specific BZDs quantification and detection methods needed for the Moroccan population.

[Generic drugs and the consumption trends of antihypertensives in Morocco]. / Les médicaments génériques et l'évolution de la consommation des antihypertenseurs au Maroc.

BACKGROUND: To evaluate the evolution of consumption of antihypertensive drugs generic among 1991-2010, to assess the impacts after the institution of Mandatory Health Insurance and the marketing of generic drugs. METHODS: We used sales data from the Moroccan subsidiary of IMS Health Intercontinental Marketing Service. RESULTS: Consumption of generic antihypertensive drugs increased from 0.08 to 10.65 DDD/1 000 inhabitants/day between 1991 and 2010. In 2010, generic of the calcium channel blockers (CCBs) represented 4.08 DDD/1 000 inhabitants/day (82.09%), followed by angiotensin converting enzyme inhibitors (ACEI) by 2.40 DDD/1 000 inhabitants/day (48.29%). The generics market of CCBs is the most dominant and represented in 2010, 79.21% in volume and 62.58% in value. CONCLUSION: In developing countries like Morocco, the generic drug is a key element for access to treatment especially for the poor population.

[Not Available]. / Les médicaments génériques et l'évolution de la consommation des antihypertenseurs au Maroc.

BACKGROUND: To evaluate the evolution of consumption of antihypertensive drugs generic among 1991-2010, to assess the impacts after the institution of Mandatory Health Insurance and the marketing of generic drugs. METHODS: We used sales data from the Moroccan subsidiary of IMS Health Intercontinental Marketing Service. RESULTS: Consumption of generic antihypertensive drugs increased from 0.08 to 10.65 DDD/1 000 inhabitants/day between 1991 and 2010. In 2010, generic of the calcium channel blockers (CCBs) represented 4.08 DDD/1 000 inhabitants/day (82.09%), followed by angiotensin converting enzyme inhibitors (ACEI) by 2.40 DDD/1 000 inhabitants/day (48.29%). The generics market of CCBs is the most dominant and represented in 2010, 79.21% in volume and 62.58% in value. CONCLUSION: In developing countries like Morocco, the generic drug is a key element for access to treatment especially for the poor population.

[Consumption analyze of the antihypertensive drugs in Morocco: period 1991-2005]. / Analyse de la consommation des antihypertenseurs au Maroc: période 1991-2005.

INTRODUCTION: The medical assumption of responsibility of the chronic diseases in Morocco, in particular arterial hypertension, remains problematic. OBJECTIVES: To evaluate the consumption, segmentation and the share of the market of generic antihypertensive drugs during the period: 1991-2005. METHODS: The data were elaborate starting from the declarations of IMS health (Intercontinental Marketing Service) for Morocco. These data related to the sales with only the pharmacies and were expressed as daily defined dose (DDD)/1000 inhabitant-days. RESULTS: The consumption of the antihypertensive drugs increased from 2 to 10 DDD/1000 between 1991 and 2005. The family of diuretics drugs was the most consumed (3.5 DDD/1000) followed by nonassociated beta-blockers (2 DDD/1000) in 2005. The segmentation was primarily represented by the diuretics (34%) and the beta-blockers (20%). The market of generic antihypertensive drugs passed from 3.3% in 1991 to 21.7% in 2005. CONCLUSION: The consumption of the antihypertensive drugs in Morocco remains too low in spite of an increasing tendency to depend especially on the generic drugs.